Clinical Fit Cadex Genomics offers Alibrex, a blood-based assay that identifies patients not responding to therapy, enabling oncology teams to adjust treatment quickly. Target oncology clinics, hospital pathology labs, and academic cancer centers that routinely monitor therapy response.

Partnership Potential With seed financing of 1.5M and a plan to expand clinical studies and IP, Cadex is positioned for co-development or licensing deals with larger diagnostics players or academic networks to scale trials, validation, and commercialization.

Value Proposition The assay is optimized to maximize negative predictive value, a differentiator for payers and providers who want to minimize false non-responders and reduce wasted treatment costs. Build materials around cost-savings, improved patient outcomes, and faster therapy decisions.

Go Market Strategy Given the small team size, Cadex may benefit from channel partnerships with distributors to reach cancer centers, and from targeted marketing to institutions actively expanding precision oncology programs.

Market Position Cadex operates in a competitive landscape with large diagnostics firms; its blood-based, therapy-response focus positions it as a specialized companion diagnostic add-on. Opportunities exist to partner or co-develop with legacy players seeking to expand liquid biopsy offerings.